Bioventus Launches New Initial Public Offering

2/10/21 Update: Bioventus announced the pricing of its initial public offering of 8 million shares at a price of $13.00 per share. The company expects gross proceeds of $104 million, or $119.6 million should the underwriters exercise their option to purchase additional shares in full. The offering is expected to close on February 16,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us